IMMUTEP Ltd (IMMP) company profile
Close on Nov 17, 2026Market cap $24.02MP/E –Yield –
About Immutep
Pharmaceutical Preparations, SIC 2834
Immutep is an enterprise involved in clinical research and development activities. The group contracts with external vendors and specialized research organizations to conduct clinical trials and manufacturing operations. It maintains intellectual property assets, including patents and licensing agreements, while administering share-based incentive programs for its personnel and directors.
The company operates through subsidiaries in France, the United States, Germany, Australia, and the Middle East. Its corporate operations and administrative oversight involve regulatory and accounting functions in Australia, where it engages independent audit services. Specific manufacturing and clinical trial functions are conducted across these international jurisdictions.
Summary of the business section of Immutep's latest annual report, written by StockData.
Company profile
Company
- Legal name
- IMMUTEP Ltd
- Headquarters
- Sydney,, C3
- Address
- Level 32, Suite 32.07 Australia Square, 264 George Street NSW 2000
- Phone
- 612 8315 7003
- Website
- immutep.com
- Employees
- 46, Jun 30, 2026
- Industry
- Pharmaceutical Preparations
- Incorporated in
- C3
- Fiscal year ends
- June 30
- Auditor
- PricewaterhouseCoopers, Sydney, Australia
Stock & identifiers
- Ticker
- IMMP
- Other tickers
- PRRUF
- Exchange
- Nasdaq
- IPO date
- Apr 19, 2012
- Shares outstanding
- 1.47B, Jun 30, 2026
- Filer category
- Accelerated filer
- Stock splits
- 1-for-20 reverse, Sep 28, 2026; 1-for-9.5 reverse, Sep 25, 2020; 1-for-3.33 reverse, Dec 28, 2016
- SEC CIK
- 1506184
- FIGI
- BBG002WD6SY6
- Share class FIGI
- BBG002WD6TP4
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Marc Voigt | See Remarks, Director | 85,700 |
| Deanne Diem Miller | Chief Operating Officer | 2,867,305 |
| Christian Mueller | Chief Development Officer | 3,774,048 |
| Stephan Karel Gerard Winckels | Chief Medical Officer | 92,935 |
| Elisabeth Amanda Boyce | Director | 423,288 |
| Pete A. Meyers | Director | 4,052,173 |
| Frederic Joseph Daniel Triebel | Director | 170,610 |
| Russell J. Howard | Director | 1,717,977 |
Employees
Headcount reported in annual reports
“As of June 30, 2026, we employed 46 people.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Dec 1, 2017 | Name change | Name changed from Prima BioMed Ltd to IMMUTEP Ltd |
See a number that looks wrong?